Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in NAFLD
NCT00303537Phase 3Unknown
- Sponsor
- Aker Hospital
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Metformin with Placebo (2 arms). Primary endpoint: Grade of steatosis as judged by repeat biopsy at 6 months. Status: unknown.
02
Drugs
metformin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT00303537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303537.